MX2020005881A - Metodos para obtener celulas derivadas de musculo. - Google Patents

Metodos para obtener celulas derivadas de musculo.

Info

Publication number
MX2020005881A
MX2020005881A MX2020005881A MX2020005881A MX2020005881A MX 2020005881 A MX2020005881 A MX 2020005881A MX 2020005881 A MX2020005881 A MX 2020005881A MX 2020005881 A MX2020005881 A MX 2020005881A MX 2020005881 A MX2020005881 A MX 2020005881A
Authority
MX
Mexico
Prior art keywords
methods
derived cells
muscle derived
obtaining muscle
obtaining
Prior art date
Application number
MX2020005881A
Other languages
English (en)
Inventor
Marco Thurner
Eva Margreiter
Wolfgang Schwaiger
Faheem Muhammad Asim
Rainer Marksteiner
Original Assignee
Innovacell Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60923243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020005881(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innovacell Biotechnologie Ag filed Critical Innovacell Biotechnologie Ag
Publication of MX2020005881A publication Critical patent/MX2020005881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/71—Oxidoreductases (EC 1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

La presente invención se refiere a métodos para obtener células derivadas del músculo esquelético (SMDC) y al uso de SMDC en un método para prevenir y/o tratar neuromiopatías y/o miopatías, en donde la neuromiopatía y/o miopatía es incontinencia, en particular una incontinencia urinaria y/o anal o fecal.
MX2020005881A 2017-12-14 2018-12-14 Metodos para obtener celulas derivadas de musculo. MX2020005881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17207417 2017-12-14
PCT/EP2018/085015 WO2019115790A1 (en) 2017-12-14 2018-12-14 Methods for obtaining muscle derived cells

Publications (1)

Publication Number Publication Date
MX2020005881A true MX2020005881A (es) 2020-08-13

Family

ID=60923243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005881A MX2020005881A (es) 2017-12-14 2018-12-14 Metodos para obtener celulas derivadas de musculo.

Country Status (24)

Country Link
US (2) US11617768B2 (es)
EP (2) EP4223872A3 (es)
JP (2) JP7361398B2 (es)
KR (1) KR20200099173A (es)
CN (1) CN111448307A (es)
AU (1) AU2018383015A1 (es)
BR (1) BR112020011853A2 (es)
CA (1) CA3085483A1 (es)
CL (1) CL2020001480A1 (es)
CY (1) CY1126049T1 (es)
DK (1) DK3724319T3 (es)
ES (1) ES2948712T3 (es)
FI (1) FI3724319T3 (es)
HR (1) HRP20230474T1 (es)
HU (1) HUE062005T2 (es)
IL (2) IL309687A (es)
LT (1) LT3724319T (es)
MX (1) MX2020005881A (es)
PL (1) PL3724319T3 (es)
PT (1) PT3724319T (es)
RS (1) RS64241B1 (es)
SI (1) SI3724319T1 (es)
WO (1) WO2019115790A1 (es)
ZA (1) ZA202002410B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423441B (zh) * 2019-09-30 2024-02-02 泰尔茂株式会社 用于提高cd56阳性细胞的比率的方法
WO2023012334A1 (en) 2021-08-06 2023-02-09 Innovacell Ag Myogenic progenitor cells for use in an optimized method for the prevention and treatment of anal incontinence

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5538722A (en) 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
WO2001078754A2 (en) 2000-04-14 2001-10-25 University Of Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
CA2461121A1 (en) 2001-09-20 2003-04-03 Kyowa Hakko Kogyo Co., Ltd. Multipotent stem cell in the interstitial tissues of skeletal muscle
EP1617852B1 (en) * 2003-04-25 2010-09-29 The University of Pittsburgh Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration
FR2890977A1 (fr) * 2005-09-19 2007-03-23 Assist Publ Hopitaux De Paris Procede d'obtention de cellules musculaires lisses humaines et leurs applications
US20070264712A1 (en) * 2006-01-10 2007-11-15 Theradigm, Inc. Expansion and differentiation of neural stem cells under low oxygen conditions
CA2722758C (en) 2007-05-29 2017-04-25 Thomas Payne Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
EP2206774A1 (en) 2008-12-23 2010-07-14 Genzyme Corporation Muscle-derived cells having differentiation capacities
CN106350480B (zh) * 2016-08-26 2019-11-08 中国农业科学院北京畜牧兽医研究所 一种纯化牛胎儿骨骼肌组织来源成肌细胞的方法
CN113614223A (zh) 2019-03-22 2021-11-05 伊诺瓦细胞股份有限公司 获得诱导性平滑肌细胞的方法

Also Published As

Publication number Publication date
US11617768B2 (en) 2023-04-04
HRP20230474T1 (hr) 2023-07-21
CL2020001480A1 (es) 2020-10-30
KR20200099173A (ko) 2020-08-21
WO2019115790A1 (en) 2019-06-20
DK3724319T3 (da) 2023-05-01
JP7361398B2 (ja) 2023-10-16
CN111448307A (zh) 2020-07-24
JP2023085507A (ja) 2023-06-20
CA3085483A1 (en) 2019-06-20
RS64241B1 (sr) 2023-06-30
FI3724319T3 (fi) 2023-05-04
BR112020011853A2 (pt) 2020-11-24
LT3724319T (lt) 2023-06-12
EP4223872A3 (en) 2023-08-23
ZA202002410B (en) 2021-09-29
PT3724319T (pt) 2023-06-07
EP4223872A2 (en) 2023-08-09
CY1126049T1 (el) 2023-11-15
ES2948712T3 (es) 2023-09-18
US20230285467A1 (en) 2023-09-14
EP3724319B1 (en) 2023-04-05
PL3724319T3 (pl) 2023-07-24
IL309687A (en) 2024-02-01
JP2021506285A (ja) 2021-02-22
SI3724319T1 (sl) 2023-07-31
IL275288A (en) 2020-07-30
HUE062005T2 (hu) 2023-09-28
US20210069255A1 (en) 2021-03-11
AU2018383015A1 (en) 2020-05-28
RU2020120580A (ru) 2022-01-14
EP3724319A1 (en) 2020-10-21

Similar Documents

Publication Publication Date Title
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
MX2018006116A (es) Materiales y metodos para el tratamiento de miopatias basadas en titina y otras titinopatias.
CA2849734C (en) Intra-vaginal devices and methods for treating fecal incontinence
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
IL279637A (en) Cell necrosis inhibitor, preparation method therefor and use thereof
CY1126049T1 (el) Μεθοδοι για ληψη κυτταρων προερχομενων απο μυες
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
GB2548234A (en) Weighted composition for treatment of a subterranean formation
MX2020000367A (es) Inhibidores de rad51.
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
WO2018160879A3 (en) Macromolecular corrosion (mcin) inhibitors: structures, methods of making and using the same
GB2539858A (en) Vaginal insert
IL251616B (en) Methods and compounds for the treatment and prevention of muscle mass loss
EP3866814A4 (en) METHOD OF GENERATING TISSUE-RESIDENT MEMORY-LIKE T-CELLS AND THEIR USE
MX2020001546A (es) Uso de inhibidores de braf para tratar reacciones cutaneas causadas por el tratamiento con un inhibidor de mek.
MX2022006746A (es) Metodo y kit para el crecimiento celular.
EP3651684A4 (en) BONE ANCHOR, KIT AND PROCESS FOR USE
MX2015000281A (es) Generacion electroquimica de derivados de urea clorados.
MX2022007647A (es) Uso de biomarcadores para evaluar la eficacia de una composición en la reducción de los efectos de la terapéutica contra el cáncer en la piel.
PH12020551206A1 (en) Farber disease markers and uses thereof
EP3749745A4 (en) TISSUE ENGINEERING SCAFFOLDING, INSTRUMENTED BIOREACTORS AND ASSOCIATED USAGE PROCEDURES
WO2015008152A3 (en) Methods and compositions for blood vessel tissue repair and engineering
EP4246324A3 (en) Apparatus and method for reducing an energy consumption of hardware based on an application state
AU2019900623A0 (en) Testing Sludge Prior to Treatment and Reuse
MX2017014217A (es) Procedimiento in vitro de proliferacion de celulas madre y uso de un dispositivo para incrementar la proliferacion de celulas madre in vitro.